Customized nanotechnology based treatment of Oral Cancer

描述(申请人提供)：根据口腔癌(OC)基金会的数据，口腔和咽癌今年将导致8000人死亡，大约每小时有一人死亡。目前，顺铂(CIS)是治疗OC的铂类化疗药物的前沿。然而，由于传统的静脉推注(IV)剂量，其疗效往往因其显著的全身毒性而受到阻碍。在这份提案中，Privo的具体目标集中在 开发和优化有效和安全的纳米工程药物输送平台，即化学晶片(CW)，重新配制已知的抗癌化疗药物(如顺铂)，用于局部和局部治疗OC，从而取代注射，提高药物的疗效 并显著降低其全身毒性。CW平台包含FDA批准的化疗药物和公认的安全(GRAS)材料。它利用纳米封装技术将药物结合到纳米粒子中，采用受控释放设计，以完全可调的和预先确定的速率释放化疗药物。这种设计有可能将高浓度的化疗药物直接输送到癌症组织，同时将对周围健康组织的毒副作用降至最低。该项目的一部分是开发一种新型双层车辆CW，由NP前端和塑化、不透气、不透水的后端组成。它由一种粘附性材料组成，单向输送药物，防止化学剂到达味蕾。这解决了令人不快的味道问题，并提高了患者的依从性。该项目可以改变OC患者的化疗治疗，用局部注射CW代替静脉注射，显著降低OC治疗的总体成本。美国癌症协会强调，口腔化疗确实是口腔癌症治疗的未来趋势，因为它为患者提供了比传统静脉注射更明显的优势。在过去的几十年里，OC患者的5年生存率并没有显著提高。此外，早期发现的存活率明显高于晚期(80-90%对25-35%)。因此， 对于癌症前期到未转移的恶性卵巢癌患者，这种重新配方的纳米胶囊CW递送平台有机会显著降低这种毁灭性癌症的发病率和死亡率。CW有可能由患者在自己家里的隐私中进行管理，避免了往返化疗诊所的不便，并降低了医疗成本。Privo Technologies的最终目标是开发和商业化一种有效、安全和方便的化疗方法，供许多OC患者使用。

DESCRIPTION (provided by applicant): According to the Oral Cancer (OC) Foundation, oral and pharyngeal cancer will cause 8,000 deaths this year, killing roughly one person per hour. Currently, cisplatin (CIS) is at the forefront of platinum- based chemotherapeutics for treating OC. However, its efficacy is often hindered by its significant systemic toxicity as a result of traditional bolus systemic intravenous (IV) doses. In this proposal, Privo's specific aims focus on developing and optimizing an effective and safe nano engineered drug delivery platform, i.e., chemo-wafer (CW) that reformulates a known anticancer chemotherapy agent ( e.g. cisplatin) for the local and topical treatment of OC, thus replacing injection, increasing the drug's efficacy and significantly reducing its systemic toxicity. The CW platform contains FDA approved chemotherapy drugs and generally recognized as safe (GRAS) materials. It utilizes nano-encapsulation techniques to incorporate drugs into NPs with a controlled-release design that releases chemo drugs at fully tunable and pre-determined rates. The design has the potential to deliver a highly concentrated amount of chemotherapy agents directly to the cancer tissue while minimizing toxic side effects to the surrounding healthy tissues. Part of the project is the development of a novel bilayered vehicle, CW, consisting of a NP front end and a plasticized, non-porous, non-permeable back end. It consists of a mucoadhesive material with unidirection delivery of the drug, which prevents the chemo agent from reaching the taste buds. This addresses the unpleasant taste issues, and increases patient compliance. This project can change the chemotherapy treatment of OC patients by replacing IV delivery with topical delivery of CW, significantly reducing the overall cost of OC treatment. The American Cancer Society has emphasized that oral chemotherapy is truly the wave of the future for oral cancer treatments because it offers patients distinct advantages over traditional IV. The 5- year survival of patient with OC has not significantly improved over the past several decades. Moreover, the survival rate for early detection is significantly higher than later stages (80-90% vs. 25- 35%). Therefore, for patients with pre-malignant to non-metastasized malignant OC, this reformulated nano-encapsulated CW delivery platform has the opportunity to considerably reduce the morbidity and mortality rate of this devastating cancer. The CW has the potential to be administered by the patient and in the privacy of their own homes, avoiding the inconvenience of travel to and from chemotherapy clinics and reducing healthcare cost. The ultimate objectives of Privo Technologies are to develop and commercialize an effective, safe and convenient chemotherapy treatment accessible to many OC patients.